HER2 POSITIVE SALIVARY GLAND CANCER

This adverse event was reported 14 times

These drugs are most commonly taken by patients reporting HER2 POSITIVE SALIVARY GLAND CANCER:

# Drug Count
0 TRASTUZUMAB 14
1 DOCETAXEL 13
2 DOCETAXEL ANHYDROUS 13
3 PERTUZUMAB 9
4 ADO-TRASTUZUMAB EMTANSINE 6
5 NIVOLUMAB 4
See all common drugs associated with HER2 POSITIVE SALIVARY GLAND CANCER

HER2 POSITIVE SALIVARY GLAND CANCER is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ADO-TRASTUZUMAB EMTANSINE 6 0.0007
1 PERTUZUMAB 9 0.0003
2 TRASTUZUMAB 14 0.0002
3 DOCETAXEL 13 0.0002
4 DOCETAXEL ANHYDROUS 13 0.0002
5 NIVOLUMAB 4 0.0000
See all drugs enriched for association with HER2 POSITIVE SALIVARY GLAND CANCER

These drug classes are most commonly taken by patients reporting HER2 POSITIVE SALIVARY GLAND CANCER:

# Drug class Count
0 HER2/neu Receptor Antagonist [EPC] 14
1 Microtubule Inhibitor [EPC] 13
2 Programmed Death Receptor-1 Blocking Antibody [EPC] 4
See all common drug classes associated with HER2 POSITIVE SALIVARY GLAND CANCER

HER2 POSITIVE SALIVARY GLAND CANCER is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 HER2/neu Receptor Antagonist [EPC] 14 0.0002
1 Microtubule Inhibitor [EPC] 13 0.0001
2 Programmed Death Receptor-1 Blocking Antibody [EPC] 4 0.0000
See all drug classes enriched for association with HER2 POSITIVE SALIVARY GLAND CANCER